Progression of Papillary Thyroid Carcinoma to Anaplastic Carcinoma in Metastatic Lymph Nodes: Solid/Insular Growth and Hobnail Cell Change in Lymph Nodes Are Predictors of Subsequent Anaplastic Transformation.
Anaplastic thyroid carcinoma
Anaplastic transformation
BRAF
Papillary thyroid carcinoma
TERT
Journal
Endocrine pathology
ISSN: 1559-0097
Titre abrégé: Endocr Pathol
Pays: United States
ID NLM: 9009288
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
accepted:
09
03
2021
pubmed:
25
3
2021
medline:
18
1
2022
entrez:
24
3
2021
Statut:
ppublish
Résumé
Most anaplastic thyroid carcinomas (ATCs) arise from papillary thyroid carcinoma (PTC). This process is also called anaplastic transformation, and the morphological harbingers of this phenomenon in nodal recurrence have not been assessed systematically. For this reason, the current study focused on features of 10 PTCs with regional lymph node recurrence that was accompanied with disease progression due to anaplastic transformation in at least one of the nodal recurrences. The findings of additional 19 PTCs which recurred without anaplastic transformation after ≥ 10 years of follow-up served as the control group. There were no clinicopathological differences between the two groups at initial surgery including age, gender, tumor size, lymph node metastasis, distant metastasis, extrathyroidal extension, histologic subtype, and treatment. The median time from the initial thyroid surgery to anaplastic transformation in the nodal recurrence was 106 months (range 6 to 437 months). Mutational analyses showed recurrent PTCs with anaplastic transformation had a high prevalence of BRAF
Identifiants
pubmed: 33761111
doi: 10.1007/s12022-021-09674-1
pii: 10.1007/s12022-021-09674-1
pmc: PMC8370965
doi:
Substances chimiques
TERT protein, human
EC 2.7.7.49
Telomerase
EC 2.7.7.49
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
347-356Informations de copyright
© 2021. The Author(s).
Références
J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404
pubmed: 14602780
J Clin Invest. 2016 Mar 1;126(3):1052-66
pubmed: 26878173
Science. 2017 Sep 29;357(6358):1416-1420
pubmed: 28818973
Am J Surg Pathol. 2001 Dec;25(12):1478-84
pubmed: 11717536
Hepatology. 2014 Dec;60(6):1983-92
pubmed: 25123086
Mod Pathol. 2020 Dec;33(12):2458-2472
pubmed: 32737449
Am J Surg Pathol. 2010 Jan;34(1):44-52
pubmed: 19956062
Nat Commun. 2019 Jun 24;10(1):2764
pubmed: 31235699
N Engl J Med. 2015 Nov 12;373(20):1926-36
pubmed: 26559571
Thyroid. 2020 Oct;30(10):1505-1517
pubmed: 32284020
Cancer. 2005 Jun 1;103(11):2261-8
pubmed: 15880523
Mol Cancer Res. 2014 Jul;12(7):979-86
pubmed: 24770869
Cell. 2014 Oct 23;159(3):676-90
pubmed: 25417114
Am J Surg Pathol. 2017 Jun;41(6):854-860
pubmed: 28009606
JAMA Oncol. 2017 Feb 1;3(2):202-208
pubmed: 27581851
Cancer. 2006 Mar 15;106(6):1286-95
pubmed: 16470605
Am J Surg Pathol. 2003 Dec;27(12):1559-64
pubmed: 14657716
Endocr J. 2008 Dec;55(6):985-9
pubmed: 18612180
Endocr Pathol. 2004 Winter;15(4):319-27
pubmed: 15681856
Nat Rev Cancer. 2006 Apr;6(4):292-306
pubmed: 16557281
Sci Rep. 2017 Feb 02;7:41752
pubmed: 28150740
Endocr Pathol. 2021 Mar;32(1):63-76
pubmed: 33543394
Brain Pathol. 2014 Mar;24(2):184-9
pubmed: 24261697
Virchows Arch. 2021 Feb;478(2):265-281
pubmed: 32683537
Cancer Res. 2013 Dec 15;73(24):7162-7
pubmed: 24121487
Am J Surg Pathol. 2007 Aug;31(8):1256-64
pubmed: 17667551
Thyroid. 2018 Jan;28(1):96-103
pubmed: 29179638
J Clin Pathol. 2019 Apr;72(4):281-284
pubmed: 30696697
Nat Rev Endocrinol. 2017 Nov;13(11):644-660
pubmed: 28707679
Mod Pathol. 2017 Nov;30(11):1527-1537
pubmed: 28731042
Head Neck Pathol. 2017 Jun;11(2):162-167
pubmed: 27550513
J Clin Oncol. 2014 Sep 1;32(25):2718-26
pubmed: 25024077
Thyroid. 2009 May;19(5):535-7
pubmed: 19348583
Endocr J. 2015;62(1):1-12
pubmed: 25195708